Targeted therapies in small cell lung cancer: A review

Aidalena Z. Abidin, Marina C. Garassino, Raffaele Califano, Amelie Harle, Fiona Blackhall

Research output: Contribution to journalArticlepeer-review


Small cell lung cancer (SCLC) is an aggressive form of lung cancer that is characterized by a rapid doubling time, early onset of dissemination and high sensitivity to chemotherapy. Despite the potential for cure in patients with limited disease with concurrent chemoradiation and an initial good response to chemotherapy in extensive disease, there is a high chance of disease relapse with an overall poor median survival for both stages. With increasing translational research and a better understanding of the molecular basis of cancer, a number of molecular targets have been identified in various preclinical studies. This review summarizes potentially viable targets and new agents that have been developed and employed in recent, ongoing and future clinical trials to attempt to improve clinical outcomes in this disease.

Original languageEnglish
Pages (from-to)25-37
Number of pages13
JournalTherapeutic Advances in Medical Oncology
Issue number1
Publication statusPublished - 2010


  • Angiogenesis inhibitors
  • Apoptosis promoters
  • BH3 mimetics
  • Cell signalling inhibitors
  • Met inhibitors
  • Multidrug resistance inhibitors
  • Small cell lung cancer (SCLC)
  • Targeted therapies
  • Vaccines

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Targeted therapies in small cell lung cancer: A review'. Together they form a unique fingerprint.

Cite this